Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture

Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05440240

Enrollment

400

Registered

2022-06-30

Start date

2023-01-10

Completion date

2030-03-31

Last updated

2023-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Connective Tissue Diseases, Contracture, Dupuytren Contracture, Dupuytren's Disease, Fibroma, Joint Diseases, Musculoskeletal Diseases, Neoplasm, Fibrous Tissue, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Connective Tissue

Keywords

Percutaneous needle fasciotomy, Corticosteroid, Randomized controlled trial

Brief summary

Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.

Interventions

PROCEDUREPercutaneous needle fasciotomy

Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre

DRUGCorticosteroid injection

Depo-Medrol

OTHERSaline injection

Isotonic saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

45 Years to 99 Years

Healthy volunteers

Inclusion criteria

Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \<20° passive extension deficit (PED), is a prerequisite for inclusion. Inclusion Criteria: * Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer * DC of either II-V finger * Well-defined/palpable cord

Exclusion criteria

* Legally incapacitated * Previous study inclusion with another finger ray * Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture \< 20° PED regardless of the deficit in the PIP or DIP joint * Previous hand surgery of the affected finger for any reason * Known allergy to the study medication * Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion) * Pregnant or lactation * Insulin dependent diabetes mellitus * Ongoing systemic infection or local infection at the site of the procedure * Rheumatoid arthritis * Amyloidosis or mucopolysaccharidosis * Unable to communicate, cooperate or participate in follow-up

Design outcomes

Primary

Measure	Time frame	Description
Recurrence rate	2 years	Recurrence is defined as 20 degrees or more passive extension deficit in metacarpophalangeal joint from baseline

Countries

Denmark

Contacts

Primary ContactLaura H Matthiesen, MS, PhD-student

lather@rm.dk004561281917

Backup ContactJeppe Lange, MD, PhD

jepplang@rm.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026